Epigenomics AG (ECXn)

1.28
+0.06(+4.92%)
  • Volume:
    76,173
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    1.26 - 1.32

ECXn Overview

Prev. Close
1.22
Day's Range
1.26-1.32
Revenue
710K
Open
1.28
52 wk Range
1.05-25.219
EPS
-1.66
Volume
76,173
Market Cap
15.13M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
31,402
P/E Ratio
-
Beta
1.07
1-Year Change
-88.8%
Shares Outstanding
11,823,227
Next Earnings Date
10 Aug 2021
What is your sentiment on Epigenomics AG?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralStrong SellSellStrong Sell
Technical IndicatorsSellBuySellStrong SellStrong Sell
SummarySellNeutralStrong SellStrong SellStrong Sell

Epigenomics AG Company Profile

Epigenomics AG Company Profile

Employees
32
Market
Germany

Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company’s products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.